Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Heeney

Showing results (121-130 of 227) with videos related to

Pageof 23
Sort By:
The Journal of General Virology|September 10, 2010
No difference in Gag and Env immune-response profiles between vaccinated and non-vaccinated rhesus macaques that control immunodeficiency virus replicationIvonne Nieuwenhuis, Niels Beenhakker, Willy M J M Bogers, et al.
Journal of Virology|November 23, 2000
Herpesvirus saimiri vFLIP provides an antiapoptotic function but is not essential for viral replication, transformation, or pathogenicityD Glykofrydes, H Niphuis, E M Kuhn, et al.
Rejuvenation Research|March 24, 2007
Old rhesus macaques treated with interleukin-7 show increased TREC levels and respond well to influenza vaccinationRichard Aspinall, Jeffrey Pido-Lopez, Nesrina Imami, et al.
The Journal of General Virology|August 11, 2004
Macaques infected long-term with attenuated simian immunodeficiency virus (SIVmac) remain resistant to wild-type challenge, despite declining cytotoxic T lymphocyte responses to an immunodominant epitopeSally A Sharpe, Alethea Cope, Stuart Dowall, et al.
Vaccine|January 27, 2004
Neutralization of primary HIV-1 SF13 can be detected in extended incubation phase assays with sera from monkeys immunized with recombinant HIV-1 SF2 gp120David Davis, Helen Donners, Betty Willems, et al.
Virology|March 11, 2006
Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infectionRong Xu, Indresh K Srivastava, Larene Kuller, et al.
Journal of Virology|June 14, 2000
Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infectionK Mori, Y Yasutomi, S Sawada, et al.
Journal of Medical Primatology|February 1, 1992
Comparison of protection from homologous cell-free vs cell-associated SIV challenge afforded by inactivated whole SIV vaccinesJ L Heeney, P de Vries, R Dubbes, et al.
The Journal of General Virology|July 23, 2004
Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimenB Mäkitalo, P Lundholm, J Hinkula, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 6, 1998
Generation of CD8 suppressor factor and beta chemokines, induced by xenogeneic immunization, in the prevention of simian immunodeficiency virus infection in macaquesY Wang, L Tao, E Mitchell, et al.
Pageof 23

Showing results (121-130 of 227) with videos related to

Sort By:
Pageof 23
The Journal of General Virology|September 10, 2010
No difference in Gag and Env immune-response profiles between vaccinated and non-vaccinated rhesus macaques that control immunodeficiency virus replicationIvonne Nieuwenhuis, Niels Beenhakker, Willy M J M Bogers, et al.
Journal of Virology|November 23, 2000
Herpesvirus saimiri vFLIP provides an antiapoptotic function but is not essential for viral replication, transformation, or pathogenicityD Glykofrydes, H Niphuis, E M Kuhn, et al.
Rejuvenation Research|March 24, 2007
Old rhesus macaques treated with interleukin-7 show increased TREC levels and respond well to influenza vaccinationRichard Aspinall, Jeffrey Pido-Lopez, Nesrina Imami, et al.
The Journal of General Virology|August 11, 2004
Macaques infected long-term with attenuated simian immunodeficiency virus (SIVmac) remain resistant to wild-type challenge, despite declining cytotoxic T lymphocyte responses to an immunodominant epitopeSally A Sharpe, Alethea Cope, Stuart Dowall, et al.
Vaccine|January 27, 2004
Neutralization of primary HIV-1 SF13 can be detected in extended incubation phase assays with sera from monkeys immunized with recombinant HIV-1 SF2 gp120David Davis, Helen Donners, Betty Willems, et al.
Virology|March 11, 2006
Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infectionRong Xu, Indresh K Srivastava, Larene Kuller, et al.
Journal of Virology|June 14, 2000
Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infectionK Mori, Y Yasutomi, S Sawada, et al.
Journal of Medical Primatology|February 1, 1992
Comparison of protection from homologous cell-free vs cell-associated SIV challenge afforded by inactivated whole SIV vaccinesJ L Heeney, P de Vries, R Dubbes, et al.
The Journal of General Virology|July 23, 2004
Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimenB Mäkitalo, P Lundholm, J Hinkula, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 6, 1998
Generation of CD8 suppressor factor and beta chemokines, induced by xenogeneic immunization, in the prevention of simian immunodeficiency virus infection in macaquesY Wang, L Tao, E Mitchell, et al.
Pageof 23